Sentences with phrase «novel small molecule inhibitor»
The authors also found that a novel small molecule inhibitor of the salvage pathway enzyme deoxycytidine kinase blocked leukemia growth in mice in combination with thymidine (to inhibit the de novo pathway).
https://www.sciencedaily.com/
Hu and his collaborator Juan R. Del Valle at the University of South Florida are developing novel small molecule inhibitors against IRE - 1 to combat cancers associated with high numbers of MDSCs.
His thesis work focused on developing novel small molecule inhibitors against protein targets such as survivin and STAT3 that are essential for progression and survival of cancer.
Not exact matches
«Our research and development team has made tremendous progress with our portfolio of novel, small molecule Naᵥ1.7 inhibitors for the treatment of acute and chronic pain,» said Stan Abel, President and Chief Executive Officer of SiteOne Therapeutics.
Therefore, a novel therapeutic approach in inflammatory breast cancer could involve a combination of conventional chemotherapy with small - molecule inhibitors of the Cdk2 cell cycle kinase.
Application of high - throughput screening to identify a novel αIIb - specific small - molecule inhibitor of αIIbβ3 - mediated platelet interaction with fibrinogen.
Identification of novel small - molecule inhibitors of glioblastoma cell growth and invasion by high - throughput screening.
UNC569, a novel small molecule Mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo.
Navire Pharma is a new company aimed at developing novel small - molecule inhibitors of a tyrosine - protein phosphatase called SHP2 (also known as PTPN11) for genetically - driven and treatment - resistant cancer.
The University of Texas MD Anderson Cancer Center and BridgeBio Pharma today announced the launch of Navire Pharma, a biopharmaceutical company aimed at developing novel small - molecule inhibitors of a tyrosine - protein phosphatase called SHP2 for genetically driven and treatment - resistant cancer.
Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma
Such a similarity makes TNFΔARE a unique model of a complex human pathology appropriate for the simoultaneous testing of novel therapeutics and small molecule inhibitors on two different pathologies.
This preclinical work led to the development of a novel anti-androgen ARN - 509, a small - molecule inhibitor discovered in collaboration with UCLA chemist Michael Jung, which targets the increased levels of androgen receptor found in hormone - refractory disease.